GlassScriptPhysician profile
Ben Shwachman
NPI 1346247335
$3,660.45
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,136 · 2020: $516 · 2021: $647 · 2022: $362.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertiflex, INC. | $1,654.36 | 2019 | |
| Collegium Pharmaceutical, INC. | $875.69 | 2019-2022 | |
| Medtronic, INC. | $372.93 | 2021-2022 | |
| Redhill Biopharma INC. | $192.21 | 2020-2022 | |
| Scilex Pharmaceuticals INC. | $183.28 | 2019-2021 | |
| Pfizer INC. | $176.55 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $105.29 | 2019-2020 | |
| Arbor Pharmaceuticals, INC. | $45.32 | 2020-2021 | |
| Almatica Pharma LLC | $25.39 | 2021 | |
| Medtronic USA, INC. | $15.44 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.99 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ben Shwachman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.